Back to top

Analyst Blog

Kohlberg Kravis Roberts & Co. L.P. (KKR - Snapshot Report) has entered the contract research business through its agreement to purchase clinical research firm PRA International from Calif.-based Genstar Capital LLC. This private equity investment firm shelled out approximately $1.3 billion for the deal.

The transaction is expected to be completed in the third quarter of this year. Credit Suisse Group AG (CS - Snapshot Report), UBS AG (UBS - Analyst Report) and Wells Fargo & Co. (WFC - Analyst Report) are acting as advisors for the deal.

PRA International, which has a record of conducting almost 2,000 clinical trials over the past 12 years, is a globally acclaimed contract research organization (CRO). Among the fastest growing companies in the CRO business, PRA International also boasts healthy client relationship and therapeutic expertise.

Private equity firm Genstar acquired PRA International in a take-private deal in 2007 for $797 million. Since then, PRA International’s European operations have been expanding, along with the company’s expertise and enhanced infrastructure. Notably, PRA International has generated higher revenues and earnings than its industry peers.

However, Genstar failed in its attempt to sell the CRO business in 2011. Recently, the market was abuzz with the news of PRA going public, similar to Quintiles Transnational Holdings Inc.

For Kohlberg Kravis Roberts, PRA marks its second healthcare investment over the past one year. In Jun 2012, it announced an investment in GenesisCare, an Australia-wide network of cancer and cardiovascular care centers. Since 1995, KKR has invested roughly $9 billion in healthcare globally.

In the recent past, the pharmaceutical industry has witnessed many mergers, with 17 moderate to large deals taking place over the last 4 years. Clinical research service firms are either being acquired by private equity firms or are becoming public, with healthy investor demand. The CRO market is expected to be more profitable, given the rising number of pharmaceutical companies that are outsourcing the research necessary to enable drugs to meet regulatory standards.

Kohlberg Kravis Roberts currently carries a Zacks Rank #3 (Hold).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 26.62 +8.70%
CENTURY ALU… CENX 27.09 +8.53%
BANCO DO BR… BDORY 16.55 +6.57%
CANADIAN SO… CSIQ 37.50 +5.50%
TESLA MOTOR… TSLA 282.88 +5.07%